Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cholesterol drug may calm inflammation after heart attack

NCT ID NCT03515304

Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether evolocumab (Repatha), a drug that lowers LDL cholesterol, can reduce inflammation and improve heart function in people who recently had a mild heart attack (NSTEMI). Sixty participants received either evolocumab or a placebo within 24 hours of admission. The main goals were to measure changes in cholesterol levels and inflammation in the heart using PET scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Evolocumab (Repatha), a drug that lowers LDL cholesterol
What this could lead to
If successful, this could show that adding evolocumab right after a heart attack reduces inflammation and improves heart recovery.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The drug is already approved for cholesterol lowering, but its benefit in acute heart attack settings is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

May 2018

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non ST segment elevation myocardial infarction * Troponin I \>/ 5.0 ng/dL * Permission of attending physician Exclusion Criteria: * ST elevation myocardial infarction * Patients requiring invasive hemodynamic support * Scheduled for cardiac surgery * Current or prior treatment with a PCSK9 antibody * Current participation in an intervention clinical trial * Female of childbearing potential who has not used acceptable method(s) of birth control for at least one month prior to screening * Contraindication to statin therapy * Subject likely not able to complete protocol related visits or procedures * Latex allergy * History of hypersensitivity to any monoclonal antibody

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute subendocardial myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome

Contacts and locations

Locations

  • Steven Paul Schulman

    Baltimore, Maryland, 21136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.